Fragile X-associated tremor/ataxia syndrome (FXTAS) …

Movement Disorders

Updated 06.19.2024
Released 09.25.2004
Expires For CME 06.19.2027

Fragile X-associated tremor/ataxia syndrome

Authors: Florian P Thomas MD MA PhD MS, Niranjan N Singh MD

See Contributor Disclosures

Editor: Robert Fekete MD

Fragile X-associated tremor/ataxia syndrome

In This Article

Quick Link

Introduction

Overview

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset triplet repeat disorder that leads to dementia, ataxia, tremor, and neuropathy. Its cause is a restricted triplet repeat expansion mutation in the fragile X mental retardation gene (FMR1), whereas a larger expansion results in fragile X syndrome A in children. Fragile X-associated tremor/ataxia syndrome affects less than 20% of female and about 50% of male carriers. In this article, the authors focus on fragile X-associated tremor/ataxia syndrome and its relation to fragile X syndrome A. Fragile X-associated tremor/ataxia syndrome illustrates the importance of obtaining a comprehensive family history that is not limited to clinical question of the patient in question. Fragile X-associated tremor/ataxia syndrome is in the differential diagnosis in patients with various combinations of the above symptoms with or without a family history of mental retardation. Some estimates suggest that as many as 1 in 3000 men above 50 years of age may develop fragile X-associated tremor/ataxia syndrome; such numbers would signify a great impact on healthcare costs. The pathomechanistic evidence of mitochondrial and RNA dysfunction and of a neurodevelopmental component to fragile X-associated tremor/ataxia syndrome is discussed.

Key points

	• Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset triplet repeat disorder that leads to dementia, ataxia, tremor, and neuropathy.
	• Normal individuals have 6 to 50 CGG repeats, carriers of the premutation have 55 to 200 repeats, and fragile X syndrome A patients have 200 to 1500 repeats with methylation at the cytosine within the CGG repeat leading to silencing of the gene.
	• Impairment of executive functioning with relative preservation of language and visuospatial skills is the hallmark of dementia.
	• Fragile X-associated tremor/ataxia syndrome affects less than 20% of female and about 50% of male carriers.
	• MRI features include brain atrophy and white matter disease, especially in the middle cerebellar peduncles, periventricular areas, and splenium of the corpus callosum.

Historical note and terminology

Researchers first began to look for a connection between fragile X syndrome A and the neurologic symptoms in elderly men when mothers of affected children noted that their children’s grandfathers became forgetful, had frequent falls, and other neurologic problems. This resulted in the recognition of a syndrome originally referred to as “intention tremor, parkinsonism, and generalized brain atrophy in male carriers of a fragile X premutation” (22).

In fragile X syndrome A, a cytosine-guanine-guanine (CGG) triplet repeat expansion in excess of 200 repeats leads to silencing of the FMR1 gene and its protein product, fragile X mental retardation protein, whereas fragile X-associated tremor/ataxia syndrome patients have a triplet repeat expansion of 55 to 200 CGG repeats.

Clinical manifestations

Presentation and course

Fragile X syndrome A is the most common form of X-linked mental retardation. Males are typically more affected than females, with IQs in the moderate to severe mental retardation range (25 to 70). One third to one half of females also has some intellectual deficit with IQs of 55 to 90. Males tend to have more severe behavioral problems. Often they have attention deficit hyperactive disorder; females may be slightly hyperactive. Anxiety and depression may be present. Some 30% of boys meet full criteria for autism, others have an abortive form (19). Inappropriate jocularity, echolalia, and perseveration occur. Ten percent to 20% of fragile X syndrome A patients have epilepsy. Seizures are commonly complex partial, less frequently partial motor, and generalized (37). Distinctive physical features of fragile X syndrome A typically appear around puberty, including connective tissue problems and macroorchidism. Patients may have long facies, prominent jaw, long widened ears, and increased head circumference. Females may have a high and arched palate. Double jointedness, ear infections secondary to floppy Eustachian tubes prior to puberty, mitral valve prolapse, aortic root dilatation, and flat feet result from connective tissue involvement.

Grandparents with fragile X-associated tremor/ataxia syndrome of children with fragile X syndrome A can present with impaired gait and fine motor skills, fluctuating weakness, numbness, neuropathic pain, erectile dysfunction, and bladder or bowel incontinence.

In males, neurologic evaluation reveals gait difficulties (95%), impaired fine motors skill (90%), cerebellar ataxia (78% to 93%), kinetic tremor (70%), parkinsonism (57%), proximal leg weakness (30%), lower extremity neuropathy (60%), autonomic dysfunction (30% to 80%) (30), and dementia (20%) (21). Impairment of executive functioning with relative preservation of language and visuospatial skills is the hallmark of dementia; this resembles frontotemporal dementia (FTD) and some of the marked and early loss of memory and language in Alzheimer disease (30; 03; 17; 05). Commonly reported neuropsychiatric symptoms include apathy, irritability, depression, disinhibition, anxiety, and delusions (05; 06). Atypical symptoms at onset include spastic paraparesis (09). There is an increased risk of sleep apnea and hypertension (25; 26). Onset, progression, and severity may be sensitive to environmental toxins including methadone (38), phenobarbital (43), and others.

Fragile X-associated tremor/ataxia syndrome affects 8% to 16% of female premutation carriers over 50 years of age with milder symptoms and fewer motor anomalies (31; 21; 04; 33). Women with the premutation may have neurocognitive dysfunction, specifically in visual attention testing (51), as well as premature ovarian failure with early menopause and infertility, and a propensity for autoimmune conditions (28; 48; 56). Executive dysfunction in premutation carriers was worse in women with fragile X-associated tremor/ataxia syndrome than those without (57). Conversion disorder has been described (46).

Prognosis and complications

The available information on fragile X-associated tremor/ataxia syndrome, being a recently described progressive neurodegenerative condition, is derived from single case reports and case series. In a retrospective longitudinal analysis of disease progression and survival in 55 men, the average age of onset was 60 years, with tremor being the first symptom. Patients began suffering falls 6 years, using a walking device 12 years, and dying 21 years after onset, respectively. Most were confined to bed with severe parkinsonian features before death (34).

Clinical vignette

At his first visit with a referral for parkinsonism, a 78-year-old man with well-controlled diabetes (HgA1c 5.5) arrived in a wheelchair. Progressive gait abnormality had started 2 years earlier, initially with difficulty standing and walking and several falls. Around that time he developed urinary incontinence and over the next year tremor and mental decline. Relatives noted that he often looked as if he were about to cry, yet he would laugh. Frequently he was unable to express himself due to word-finding difficulties. His short-term memory had significantly declined. Three months before the visit he stopped driving after he was pulled over by the police several times for swerving. Levodopa/carbidopa for his tremor and gait difficulties was of no benefit.

His mini-mental status exam score was 22/30 with deficits in recall, attention, and construction. He had mild ptosis of the left eye, a diminished left nasolabial fold, and mask-like facies. Jaw jerk and snout reflexes were present. He had a prominent action tremor and cogwheeling. Power was 4/5 diffusely. Ankle jerks were absent, and plantar responses were extensor. Sensation was impaired distally. His gait was ataxic, and a Romberg sign was present.

His daughter remarked that the mental status testing resembled the exam her 11-year-old son had undergone during an evaluation, which led to a genetically confirmed diagnosis of fragile X syndrome A. Her sister also had a son with fragile X syndrome A.

A CT showed enlarged ventricles and cortical atrophy, but MR imaging was not possible due to a pacemaker. Nerve conduction studies revealed a generalized sensorimotor polyneuropathy. The following blood tests were normal: rheumatoid factor, ANA, hepatitis B and C, syphilis serology, TSH, folate, and B12 (579). Fragile X testing revealed a 112 CGG repeat expansion in the fragile X syndrome A gene.

With donepezil, the mini-mental status exam score improved slightly to 25/30.

Biological basis

Etiology and pathogenesis

In fragile X syndrome A and fragile X-associated tremor/ataxia syndrome, there is a CGG expansion in the 5’ promoter region of the FMR1 gene on chromosome Xq27.3. Normal individuals have 6 to 50 CGG repeats, carriers of the premutation have 55 to 200 repeats, and fragile X syndrome A patients have 200 to 1500 repeats with methylation at the cytosine within the CGG repeat leading to silencing of the gene. Normal individuals and carriers do not have methylation of their CGG expansions (39). Rare patients have 45 to 54 repeats or an unmethylated full mutation (18). In analogy to other triplet repeat disorders, fragile X syndrome A may also result from a point mutation in FMR1 or an FMR1 deletion. Maternal transmission is more likely to result in a greater CGG triplet repeat expansion and a more severe and earlier form of the disease.

In fragile X syndrome A, the long stretch of methylated DNA repeat sequences in the promoter leads to reduced gene expression of the FMR1 gene and its protein product, fragile X mental retardation protein. This is an RNA binding protein that affects splicing, stability, transport, and translation, and, thus, may affect activity of multiple genes expressed in different organs, resulting in age-dependent abnormalities in several organ systems (see above), ie, facial, skeletal and cardiovascular, central nervous system, peripheral nervous system, and endocrine abnormalities. Its role in RNA translation in the brain remains controversial; however, fragile X mental retardation protein forms complexes with cortical brain polyribosomes (50). Fragile X mental retardation protein may also function as a DNA-binding protein and transcription factor.

In fragile X-associated tremor/ataxia syndrome, fragile X mental retardation protein blood levels are near normal or mildly reduced. FMR1 mRNA levels are elevated two to four times in men with alleles in the low mutation range of 55 to 100 CGG repeats, and 4 to 10 times in men with 100 to 200 CGG repeats. Elevated mRNA levels also occur in women with premutation alleles (54). This may represent a reduced translational efficiency of the FMR1 gene; the elevated level may have a cumulative cytotoxic effect leading to inclusion body formation discussed below (16).

As women have two X chromosomes, lyonization, the random inactivation of the normal versus abnormal X chromosome, results in phenotypic variability: Thus, some female carriers may have normal fragile X mental retardation protein (48; 29). The presence and severity of ataxia correlates with increasing CGG repeat length when the percentage of normal alleles that are active is considered (33).

Histological and molecular autopsy studies of the brains of patients with the premutation reveal accumulations of abnormal cellular material as nuclear cortical, brainstem neuronal, and astroglial inclusion bodies and marked spongiosis of the deep cerebellar white matter (16). Inclusion bodies were found in all autopsied female carriers, even in two without fragile X-associated tremor/ataxia syndrome (53). Spongiosis was seen in the middle cerebellar peduncle (MCP) in seven of eight cases, which correlates with the characteristic T2 signal change (MCP sign) seen in many patients (15; 03). Inclusion bodies are concentrated in the hippocampus and frontal cortical regions, areas that control movement and are important in learning, memory, and emotions. Their location has been correlated with clinical symptoms and MRI findings (30). Inclusion bodies are also specifically concentrated in the hypoglossal nucleus and in spinal cord autonomic neurons, which may explain the dysphagia and autonomic involvement (15). The authors found a correlation between the repeat number and intranuclear astroglial and neuronal inclusions. Interestingly, fragile X syndrome A patients with the full mutation do not have inclusion body formation (41). Binding of ubiquitin antibodies to these inclusions suggests that they are somehow related to degradation of as yet unknown proteins; neurodegeneration may result from the inability of affected cells to degrade abnormal proteins (16). Intranuclear inclusions also occur in the ganglion cells of adrenal medulla, dorsal root ganglia, paraspinal sympathetic ganglia, myenteric ganglia, and subepicardial autonomic ganglion (14). In vitro studies reveal mitochondrial dysfunction that may sensitize carriers to environmental stressors that, in turn, trigger the clinical features (42). Furthermore, there is evidence of an RNA gain-of-function mechanism (44). A mouse model displayed embryonic neocortical migration defects and altered neuronal marker expression, consistent with neurodevelopmental abnormalities (10).

Diagnostic workup

Recommendations for definite, probable, or possible fragile X-associated tremor/ataxia syndrome based on clinical appearance and radiographical findings have been suggested (30). Typical findings of brain MRI include ventricular enlargement, severe frontoparietal volume loss, and cerebellar hyperintensities and atrophy. The changes on neuroimaging are milder in females compared to males. Middle cerebellar peduncle T2 hyperintensity (the characteristic MCP sign) is seen in 13% of females compared to 58% males with fragile X-associated tremor/ataxia syndrome (01). MRI changes may precede the neurologic deterioration, and there may be significant discrepancy (35).

Decreased middle cerebellar peduncle (MCP) width may be one of the earliest signs in FXTAS. In a study involving 53 male patients with FXTAS and 61 controls with an average follow-up for 1.96 years, MCP width was initially reduced in a subset of premutation carriers who developed FXTAS and also decreased over time during follow-up (47).

Hall and colleagues recommended FMR1 testing for unexplained late-onset cerebellar ataxia in men over 50 years of age or for patients with Parkinson disease or fragile X-associated tremor/ataxia syndrome phenotype with either the MCP sign on MRI or with a family history of developmental delay, autism, mental retardation, or premature ovarian failure (23; 24). Neuropsychological evaluation can document the degree of cognitive involvement and characterize it as dysexecutive (07). Neurophysiological abnormalities of peripheral neuropathy, if present, include reduced tibial nerve conduction velocities and prolonged F-wave latencies (49). Histological changes include dystrophic white matter and astrocytic and neuronal intranuclear inclusions with increased putaminal iron deposits (02). These inclusions may result from a triplet repeat-triggered cryptic polyglycine-containing protein (55). Other coexisting causes of peripheral neuropathies must be addressed, including infectious, endocrinological, and immunological abnormalities, vitamin deficiencies, and nerve compression. The same tests may reveal additional causes for mental decline.

Longitudinal development over 4 to 5 years of deficits in executive and motor function were described in 64 male premutation carriers and may represent a prodrome to the movement disorder (12; 27).

References

01: Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007;69(9):851-9. PMID 17724287
02: Ariza J, Rogers H, Hartvigsen A, et al. Iron accumulation and dysregulation in the putamen in fragile X-associated tremor/ataxia syndrome. Mov Disord 2017;32(4):585-91. PMID 28233916
03: Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007;22(14):2018-30. PMID 17618523
04: Biancalana V, Toft M, Le Ber I, et al. FMR1 premutation associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. Arch Neurol 2005;62(6):962-6. PMID 15956167
05: Bourgeois J, Coffey S, Rivera SM. Fragile X premutation disorders – expanding the psychiatric perspective. J Clin Psychiatry 2009;70(6):852-62. PMID 19422761
06: Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile x permutation carriers. J Clin Psychiatry 2011;72(2):175-82. PMID 20816038
07: Brega AG, Goodrich G, Bennett RE, et al. The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. J Clin Exp Neuropsychol 2008;15:11-17. PMID 18608667
08: Brussino A, Gellera C, Saluto A, et al. FMR1 gene premutation is a frequent cause of late-onset sporadic cerebellar ataxia. Neurology 2005;64(1):145-47. PMID 15642922
09: Cellini E, Forleo P, Ginestroni A, et al. Fragile X premutation with atypical symptoms at onset. Arch Neurol 2006;63(8):1135-8. PMID 16908740
10: Cunningham CL, Martínez Cerdeño V, Navarro Porras E, et al. Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet 2011;20(1):64-79. PMID 20935171
11: Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. JAMA 2004;292(14):1685-6. PMID 15479932
12: Famula J, Ferrer E, Hagerman RJ, et al. Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. J Neurodev Disord 2022;14(1):23. PMID 35321639
13: Gane LW, Iosif AM, Flynn-Wilson L, Venturino M, Hagerman RJ, Seritan AL. Assessment of patient and caregiver needs in fragile X-associated tremor/ataxia syndrome by utilizing Q-sort methodology. Aging Ment Health 2010;14(8):1000-7. PMID 21069606
14: Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 2009;29(3):280-4. PMID 18627480
15: Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129(Pt 1):243-55. PMID 16332642
16: Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002;125(Pt 8):1760-71. PMID 12135967
17: Grigsby J, Brega AG, Leehey MA, et al. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ ataxia syndrome. Mov Disord 2007;22(5):645-50. PMID 17266074
18: Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci 2015;1338:58-70. PMID 25622649
19: Hagerman R, Hoem G, Hagerman P. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism 2010;1(1):12. PMID 20858229
20: Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008;3(2):251-62. PMID 18686748
21: Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004;74(5):1051-6. PMID 15065016
22: Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57(1):127-30. PMID 11445641
23: Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnosis of the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005;65(2):299-301. PMID 16043804
24: Hall DA, Howard K, Hagerman R, Leehey MA. Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord 2009;15(2):156-9. PMID 18565783
25: Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet 2011;156B:923-8. PMID 21932336
26: Hamlin AA, Sukharev D, Campos L, et al. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A 2012;158A:1304-9. PMID 22528549
27: Hessl D, Mandujano Rojas K, et al. FMR1 Carriers report executive function changes prior to Fragile X-associated tremor/ataxia syndrome: a longitudinal study. Mov Disord 2024;39:519-25. PMID 38124331
28: Hundscheid RD, Sistermans EA, Thomas CM, et al. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet 2000;66(2):413-8. PMID 10677300
29: Hundscheid RD, Smits AP, Thomas CM, Kiemeney LA, Braat DD. Female carriers of fragile X premutations have no increased risk for additional diseases other than premature ovarian failure. Am J Med Genet 2003;117A(1):6-9. PMID 12548733
30: Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72(4):869-78. PMID 12638084
31: Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004;291(4):460-9. PMID 14747503
32: Leehey M, Munhoz R, Lang AE, et al. The fragile X premutation presenting as essential tremor. Arch Neurol 2003;60(1):117-21. PMID 12533098
33: Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008;70(16 Pt 2):1397-402. PMID 18057320
34: Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007;22(2):203-6. PMID 17133502
35: Loesch DZ, Litewka L, Churchyard A, Gould E, Tassone F, Cook M. Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats. J Clin Neurosci 2007;14(3):245-8. PMID 17194594
36: Musci TJ, Moyer K. Prenatal carrier testing for fragile X: counseling issues and challenges. Obstet Gynecol Clin North Am 2010;37(1):61-70. PMID 20494258
37: Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999;40(8):1092-9. PMID 10448821
38: Muzar Z, Lozano R, Schneider A, et al. Methadone use in a male with the FMRI premutation and FXTAS. Am J Med Genet A 2015;167(6):1354-9. PMID 25900641
39: O'Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002;25:315-38. PMID 12052912
40: Park JH, Jang W, Youn J, et al. Prevalence of fragile X-associated tremor/ataxia syndrome: a survey of essential tremor patients with cerebellar signs or extrapyramidal signs. Brain Behav 2019;9(7):e01337. PMID 31158927
41: Reyniers E, Martin JJ, Cras P, et al. Postmortem examination of two fragile X brothers with an FMR1 full mutation. Am J Med Genet 1999;84(3):245-9. PMID 10331601
42: Ross-Inta C, Omanska-Klusek A, Wong S, et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 2010;429(3):545-52. PMID 20513237
43: Saldarriaga, W, Lein P, González Teshima LY, et al. Phenobarbital use and neurological problems in FMR1 premutation carriers. Neurotoxicology 2016;53:141-7. PMID 26802682
44: Sellier C, Rau F, Liu Y, et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 2010;29(7):1248-61. PMID 20186122
45: Seritan AL, Nguyen DV, Mu Y, et al. Memantine for fragile X-associated tremor/ ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2014;75(3):264-71. PMID 24345444
46: Seritan AL, Schneider A, Olichney JM, et al. Conversion disorder in women with the FMR1 premutation. Am J Med Genet A 2009;149A(11):2501-6. PMID 19842197
47: Shelton AL, Wang JY, Fourie E, et al. Middle cerebellar peduncle width-a novel mri biomarker forFXTAS? Front Neurosci 2018;12:379. PMID 29988561
48: Sherman SL. Premature ovarian failure among fragile X premutation carriers: parent-of-origin effect. Am J Hum Genet 2000;67(1):11-3. PMID 10848491
49: Soontarapornchai K, Maselli R, Fenton-Farrell G, et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008;65(4):495-8. PMID 18413472
50: Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci 2004;24(33):9272-6. PMID 15317853
51: Steyaert J, Legius E, Borghgraef M, Fryns JP. A distinct neurocognitive phenotype in female fragile-X premutation carriers assessed with visual attention tasks. Am J Med Genet 2003;116A(1):44-51. PMID 12476450
52: Tan EK, Zhao Y, Puong KY, et al. Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort. Neurology 2004;63(2):362-3. PMID 15277639
53: Tassone F, Greco CM, Hunsaker MR, et al. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav 2012;11(5):577-85. PMID 22463693
54: Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66(1):6-15. PMID 10631132
55: Todd, PK, Oh SY, Krans A, et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013;78(3):440-55. PMID 23602499
56: Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A 2012;158A(10):2473-81. PMID 22903889
57: Yang JC, Simon C, Niu YQ, et al. Phenotypes of hypofrontality in older female fragile x premutation carriers. Ann Neurol 2013;74(2):275-83. PMID 23686745
58: Zhao C, Liu Y, Wang Y, et al. A Chinese case of fragile X-associated tremor/ataxia syndrome (FXTAS) with orthostatic tremor: case report and literature review on tremor in FXTAS. BMC Neurol 2020;20(1):145. PMID 32312236

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Florian P Thomas MD MA PhD MS

Dr. Thomas of Hackensack Meridian School of Medicine had no relevant financial relationships to disclose.
See Profile
Niranjan N Singh MD

Dr. Singh of the University of Missouri-Columbia received honorariums from AbbVie for speaking engagements.
See Profile

Editor

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

Justin A Malone MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: male: female >2:1
Heredity: heredity typical

X-linked
Population groups selectively affected: Fragile X premutation carriers
Occupation groups selectively affected: None

ICD & OMIM codes

ICD-10: Alzheimer disease: G30

Dementia in Alzheimer disease: F00

Essential tremor: G25.0

Fragile X syndrome A: Q99.2

Peripheral neuropathy: G64

Unspecified dementia: F03

Other vascular dementia: F01.8
ICD-11: Other specified hereditary ataxia: 8A03.1Y

Tremor due to certain specified central nervous system diseases: 8A04.33
OMIM: Fragile X syndrome A: *309550

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Fragile X-associated tremor/ataxia syndrome

Associated Disorders

Cerebellar ataxia
Dementia
Parkinsonism
Peripheral neuropathy

Differential Diagnosis

Alzheimer disease
ataxia
multiple system atrophy
Parkinson disease
progressive supranuclear palsy
- peripheral neuropathy
- tremor

Fragile X-associated tremor/ataxia syndrome (FXTAS) …

Fragile X-associated tremor/ataxia syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Fragile X-associated tremor/ataxia syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.